Trial Profile
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs IMC CS4 (Primary)
- Indications Advanced breast cancer; Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly and Company
- 26 Aug 2020 Results published in the Clinical Cancer Research
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 15 May 2019 According to a Eli Lilly media release, data from this trial will be presented at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019.